- Poster presentation
- Open Access
Economic impact and cost-effectiveness of urine neutrophil gelatinase-associated lipocalin following cardiac surgery
© BioMed Central Ltd. 2010
- Published: 1 March 2010
- Base Case
- Coronary Artery Bypass
- Acute Kidney Injury
- Probabilistic Sensitivity Analysis
- Decision Analysis Model
Acute kidney injury (AKI) is common after cardiac surgery and recognition with specific biomarkers may improve outcome. We assessed the impact and cost-effectiveness (CE) of urine neutrophil gelatinase-associated lipocalin (uNGAL) for AKI diagnosis compared with current methods.
We developed a decision analysis model to evaluate the CE of uNGAL plus standard diagnostic tests (for example, BUN, creatinine) compared with standard methods alone. The model was developed from the UK societal using costs per quality-adjusted life years (QALY). Model parameters were derived from the literature, UK economic data, and MD interviews. The base case was a 68-year-old male patient undergoing coronary artery bypass surgery. Sensitivity analyses were performed to determine how CE would vary with changes in the underlying model variables.
Use of uNGAL appears to be cost-effective in the diagnosis of AKI after cardiac surgery.